Featured Publications
Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
Molassiotis A, Cheng H, Lopez V, Au J, Chan A, Bandla A, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19: 132. PMID: 30736741, PMCID: PMC6368751, DOI: 10.1186/s12885-019-5302-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesDose-Response Relationship, DrugFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasm StagingNeoplasmsPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPrevalenceProspective StudiesQuality of LifeSeverity of Illness IndexConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNeurotoxic chemotherapyPrevalence of sensory neuropathyCohort study of patientsCumulative chemotherapy dosePlatinum-based chemotherapyLongitudinal cohort study of patientsMeasuring chemotherapy-induced peripheral neuropathyStudy of patientsNerve conduction studiesAssessment of chemotherapy-induced peripheral neuropathyCIPN incidencePatient-reported outcome measuresAssociated with onsetLongitudinal cohort studyChemotherapy doseMotor neurotoxicityClinician-based scalesMotor neuropathySensory neuropathyChemotherapyNeuropathyNatural historyPatients
2021
Small bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes
Chin Y, Jain S, Lee M, Ng C, Lin S, Mai A, Muthiah M, Foo F, Sundar R, Ong D, Leow W, Leong R, Chan W. Small bowel adenocarcinoma in Crohn’s disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. International Journal Of Colorectal Disease 2021, 37: 239-250. PMID: 34704127, DOI: 10.1007/s00384-021-04050-1.Peer-Reviewed Original ResearchConceptsMolecular analysis findingsCrohn's diseaseOverall survivalClinical presentationBowel adenocarcinomaCD patientsInflammatory bowel disease patientsMeta-analysisSmall bowel adenocarcinomaAssociated with Crohn's diseaseConclusionOur meta-analysisMethodsElectronic databases MedlineStatistically significant increaseEpithelial dysplasiaAbdominal painMismatch repair deficiencyKRAS mutationsRadiological featuresHistopathological findingsGenetic mutationsPatientsRepair deficiencyResultsIn totalDisease patientsHistopathology
2019
Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
Molassiotis A, Cheng H, Leung K, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Lopez V. Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy. Brain And Behavior 2019, 9: e01312. PMID: 31063261, PMCID: PMC6576180, DOI: 10.1002/brb3.1312.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyDevelopment of chemotherapy-induced peripheral neuropathyHistory of neuropathyRisk factorsPeripheral neuropathyPlatinum-based chemotherapySymptom burdenPotential risk factorsVegetable/fruit intakeWHO criteriaChemotherapy cyclesAlcohol intakeSmoking historyUnivariate analysisChemotherapyMultivariate regression modelMedical historyTreatment characteristicsNeurotoxic chemotherapyKey risk factorsNeuropathyCancer CenterSide effectsQuality of lifeTreatment decisions